Sisram Medical Ltd (SISRAM MED) disclosed a share repurchase of 79,200 ordinary shares on 13 October 2026, executed on the Hong Kong Stock Exchange under its 24 June 2026 general mandate. The shares were bought back at prices ranging from HKD 1.96 to HKD 2.00, translating to a volume-weighted average cost of HKD 1.9843 and an aggregate consideration of approximately HKD 0.16 million.

Following the transaction, Sisram’s issued share capital (excluding treasury shares) fell marginally by 0.02 % to 468.14 million shares. Treasury stock rose to 198,400 shares, while total issued shares remained unchanged at 468.34 million because the repurchased shares are being held in treasury rather than cancelled.

To date, Sisram has repurchased 198,400 shares under the current mandate, representing 0.042 % of the company’s outstanding shares at the mandate’s adoption. In line with Hong Kong Listing Rules, the company is subject to a moratorium on new share issues or further treasury share sales until 12 November 2026.